Better Therapeutics Announces Publication Of LivVita Liver Disease Study Results In Gastro Hep Advances
Portfolio Pulse from Benzinga Newsdesk
Better Therapeutics, Inc. (NASDAQ:BTTX) has announced the publication of the LivVita study's results, which indicate the potential of its digitally delivered Cognitive Behavioral Therapy to address unmet clinical needs in MASLD and MASH. The study met its primary endpoint by reducing liver fat within 90 days and achieved key secondary endpoints related to improved liver health. The company plans to submit a request to the FDA for Breakthrough Device Designation by the end of 2023.
October 05, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Better Therapeutics' LivVita study results indicate the potential of its digital therapy for MASLD and MASH, which could lead to FDA Breakthrough Device Designation. This could positively impact the company's stock in the short term.
The positive results from the LivVita study indicate the potential of Better Therapeutics' digital therapy for MASLD and MASH. If the company successfully submits a request to the FDA for Breakthrough Device Designation, it could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100